Opzelura Experience Study

Opzelura Experience Study

Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.

Patients' adherence to even one topical treatment is often poor. Even giving patients two treatments reduces treatment adherence compared to one treatment alone. Complicating the treatment with numerous medications along with lifestyle changes may be overwhelming and counterproductive to patients' outcomes. The availability of topical ruxolitinib (Opzelura) provides an opportunity to give patients a highly effective treatment that, unlike standard topical steroids of variable potency, can be used on all areas, even on the face and body folds, and without long-term adverse outcomes. In theory, this offers an opportunity to improve atopic dermatitis (AD) outcomes by simplifying patients' treatment.

Inclusion Criteria:

• Patients ≥2 years of age
• Patients with a current diagnosis of atopic dermatitis that is mild-to-moderate in severity and in ≥2 body areas
• Patients with up to 20% total body surface area involvement
• Women of childbearing age taking/using a contraceptive

Exclusion Criteria:

• Patients without a current diagnosis of atopic dermatitis
• Patients who are prescribed changing systemic medications or treatments (phototherapy, biologics) for atopic dermatitis
• Patients who would require use of other topical medications for other diagnoses (tretinoin, clindamycin)
• Patients with areas of skin with active infection
• Patients who are pregnant